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Abstract
Background: Alternative N-glycosylation has significant structural and functional consequences on immunoglobulin
G (IgG) and can affect immune responses, acting as a switch between pro- and anti-inflammatory IgG functionality.
Studies have demonstrated that IgG N-glycosylation is associated with ageing, body mass index, type 2 diabetes and
hypertension.
Methods: Herein, we have demonstrated patterns of IgG glycosylation that are associated with blood lipids in a
cross-sectional study including 598 Han Chinese aged 20–68 years. The IgG glycome composition was analysed by
ultra-performance liquid chromatography.
Results: Blood lipids were positively correlated with glycan peak GP6, whereas they were negatively correlated
with GP18 (P < 0.05/57). The canonical correlation analysis indicated that initial N-glycan structures, including GP4,
GP6, GP9-12, GP14, GP17, GP18 and GP23, were significantly correlated with blood lipids, including total cholesterol,
total triglycerides (TG) and low-density lipoprotein (r = 0.390, P < 0.001). IgG glycans patterns were able to distin‑
guish patients with dyslipidaemia from the controls, with an area under the curve of 0.692 (95% confidence interval
0.644–0.740).
Conclusions: Our findings indicated that a possible association between blood lipids and the observed loss of galac‑
tose and sialic acid, as well as the addition of bisecting GlcNAcs, which might be related to the chronic inflammation
accompanying with the development and procession of dyslipidaemia.
Keywords: Immunoglobulin G, N-Glycosylation, Blood lipids, Dyslipidaemia
Background
Glycosylation is an essential posttranslational modification of proteins. It is an integral part of proteins and
significantly contributes to their structure and function
[1–3]. Immunoglobulin G (IgG) plays an important role
in the human immune system, and N-glycans attach to
the conserved asparagine 297 in the fragment crystallizable (Fc) part of this molecule and act as a switch between
pro- and anti-inflammatory IgG functionality [1, 4–6].
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IgG N-glycosylation impacts the physiology and malfunction of the immune system, and aberrant IgG N-glycosylation is involved in several inflammatory and chronic
diseases [7–10]. Previous studies have revealed that
genetic loci associated with variation in IgG glycosylation are also known risk factors for several inflammatory
diseases and chronic diseases [11, 12], indicating that
IgG glycosylation is not merely a result of complicated
enzymatic activities, but is a subtly regulated outcome
designed to meet dominant physiological needs.
It is widely recognized that dyslipidaemia is associated
with an increased risk of coronary artery disease, stroke,
and heart failure [13–16]. However, the mechanisms by
which dyslipidaemia increase the risk of these diseases
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has not been completely elucidated. Importantly, dyslipidaemia is responsive to changes in systemic inflammation, a recognized causal pathway of cardiovascular and
cerebrovascular diseases [17–22]. Epidemiological evidence has indicated that blood lipids are associated with
several inflammatory markers, such as cytokines and
chemokines [17, 23]. Due to the inflammatory role of IgG
N-glycosylation, together with its association with ageing
[24], obesity [25], type 2 diabetes [26], hypertension [27,
28], ischemic stroke [29], Parkinson’s disease [30] and
cancer [31], it can be speculated that blood lipids may be
associated with the N-glycosylation of IgG.
In this study, we aimed to determine the association
between the IgG N-glycome and blood lipids, including total cholesterol (TC), total triglycerides (TG), highdensity lipoprotein (HDL), and low-density lipoprotein
(LDL), and explored the use of IgG glycans as biomarkers
to diagnose dyslipidaemia to further investigate the role
of IgG glycosylation in dyslipidaemia.

Methods
Ethical approval

Written informed consent was obtained from each subject at the beginning of the study, and the study has been
approved by the Ethics Committee of the Capital Medical
University, Beijing, China. The ethics approval was given
in compliance with the Declaration of Helsinki [32].
Participant recruitment

An observational cross-sectional study was conducted
during 2012, with a total of 913 participants of Chinese
Han ancestry who were recruited from a communitybased survey in Beijing [24, 27]. All participants were
required to meet the following inclusion criteria: (1)
age equal to or greater than 18 years; (2) no medication history during the previous 2 weeks; and (3) signed
informed consent prior to participation. Individuals were
excluded based on the following criteria: (1) pregnant or
lactating women; (2) history of mental illness or infectious disease; and (3) history of malignant tumor, stroke
or other cerebrovascular disease, congenital heart disease, acute myocardial infarction, liver disease, renal failure, chronic obstructive pulmonary disease, rheumatoid
arthritis or other disease.
Diagnosis of dyslipidaemia

According to the Chinese guidelines for the prevention
and control of dyslipidaemia in adults [33], the participants were grouped into cases with TC ≥ 6.2 mmol/L
(defined as hypercholesteremia), TG ≥ 2.3 mmol/L
(defined as hypertriglyceridemia), HDL < 1.0 mmol/L
(defined as the decreased HDL), or LDL ≥ 4.1 mmol/L
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(defined as the elevated LDL). The controls were those
who did not have dyslipidaemia at the time of the study.
Covariates

Each participant was required to complete a thorough
health examination, which included anthropometric
measurements and an analysis of the physical and chemical properties of a blood sample. Detailed information
about subject recruitment and enrolment has been previously described [24, 27]. As in our previous study [24],
12 clinical traits (age, sex, body mass index (BMI), waist–
hip ratio (WHR), systolic blood pressure (SBP), diastolic
blood pressure (DBP), fasting blood triglycerides (FBG),
resting heart rate (RHR), TC, TG, HDL and LDL) were
assessed in the current study [24].
To obtain the anthropometric trait data, physical
examinations and interviews were carried out by trained
nurses and physicians. The BMI was calculated by the formula weight (in kilograms)/height2 (in metres squared).
The SBP and DBP were measured twice on the right arm
using a standard mercury sphygmomanometer after the
subjects had rested for at least 10 min in a sitting position [34]. For the blood parameters (haematology and
biochemical traits), fasting blood samples were collected
in the morning after an overnight fast by venepuncture.
All collected blood samples were processed within 8 h
and blood plasma which was separated from whole blood
was stored in freezers (− 80 °C) before the measurements. Haematology and biochemical parameters were
measured by standard blood chemistry and haematology
assays (Hitachi Automatic Analyzer, Model-7600, Tokyo,
Japan), which were conducted at the Medical Laboratory
of Beijing Xuanwu Hospital, Beijing.
IgG N‑glycan analysis

As previously reported, IgG was first isolated from
human plasma [24, 35]. The IgG N-glycans were cleaved
and analysed by hydrophilic interaction chromatography (HILIC)- ultra-performance liquid chromatography (UPLC) as previously described [35]. In brief, after
washing and equilibrating the protein G monolithic
plates, 50 µL of plasma was diluted 10× with binding
buffer (1× phosphate-buffered saline, pH 7.4), applied to
the protein G plates, and immediately washed. The IgGs
were eluted with 1 mL of 0.1 M formic acid and immediately neutralized with 1 M ammonium bicarbonate.
Next, the IgG N-glycans cleavage and labelling were
performed. The released N-glycans were labelled with
2-aminobenzamide, a fluorescent dye used to visualize
glycans by UPLC, by multistage mixing with 2-aminobenzamide, dimethyl sulfoxide, glacial acetic acid, and
2-picoline borane. Finally, the IgG N-glycans were analysed by HILIC–UPLC in 24 IgG glycan peaks (GPs). The
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glycan structures of the glycans per peak were previously
reported, and a detailed description is shown in Additional file 1: Table S1 [35]. The normalization and batch
correction of the UPLC data was detailed in a previous
study [24, 35]. The total area normalization was applied
where the amount of glycans in each peak was expressed
as a percentage of the total integrated area. The calculation formula is shown in Additional file 1: Table S1.
Among the 24 initial GPs, GP3 was excluded as it did
not pass quality control tests. An additional 54 derived
traits were calculated for the remaining 23 initial glycans
[35]. Of the derived traits, 34 were of interest and were
included in the analysis describing the relative abundances of galactosylation, sialylation, bisecting GlcNAc
and core fucosylation (Additional file 2: Table S2).
Statistical analysis

The normal distribution of glycans was tested by the Kolmogorov–Smirnov test where P < 0.10 was considered to
be statistically significant. Continuous variables underlying the normal distribution were represented as the
mean ± standard deviation (SD), otherwise the medians
(interquartile ranges) were used. The difference of continuous variables between two groups was tested using
Student’s t test or the Wilcoxon rank-sum test. Categorical variables were represented as n (proportion), and the
between-group differences were tested by the Chi square
test. For the normally distributed variables, including age,
BMI, WHR, SBP, DBP, FBG and RHR, t-tests were used
to compare the differences between two groups. A generalized linear model (GLM) [36] was fitted to estimate
the effect of blood lipids on glycosylation when adjusting
for confounding factors, including age, sex, BMI, WHR,
SBP, DBP, FBG and RHR, because most of the glycans
(dependent variables) were not normally distributed.
There were internal associations among the independent
variables, which could have induced multi-collinearity
in the statistical models. Therefore, principal component analysis (PCA) [37] was used to combine variables
to principal components before the regression analysis.
Moreover, these principal components were used in the
multiple variables association analysis instead of the original variables. The internal associations among the independent variables were analysed using by the R package
“corrplot” [38].
Before correlation and regression analysis, the z-score
of normalized transformations for IgG N-glycans was
applied to add the consistent comparability among IgG
N-glycans. Canonical correlation analysis (CCA) [40] was
used to determine two sets of variables of the initial glycan structures (x) and the blood lipids (y) and to find the
overall correlation between the two sets of variables. The
identified variables with a statistically significant impact
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on the canonical variables were judged by the canonical
loadings. Generally, absolute values greater than 0.30 are
considered to be significant loadings [39].
To explore IgG N-glycans as biomarkers to diagnose
dyslipidaemia, 23 initial glycans were used as predictors. Logistic regression was performed to identify the
23 glycans that were respectively related to cases’ status after adjusting for the effect of age, sex, BMI, WHR,
SBP, DBP, FBG and RHR. Considering the internal associations among these variables, we chose to correct sex,
Prin.1 and Prin.2 instead of the original variables. The
significant glycans were presented as the odds ratio (OR)
with a 95% confidence interval (CI) and were graphed
by a forest plot, which was generated using the R package “forestplot” [40]. Next, a classification model was
established based on the significant glycans. Considering
that there were internal associations in the glycans that
might have induced multicollinearity in the model, the
least absolute shrinkage and selection operator (LASSO)
method was used to select glycans to reduce the dimension of data. The LASSO method was carried out by the
R package “lars” [41]. The logistic regression model was
then used to assess the discrimination of dyslipidaemia
by combining the glycans left by the LASSO method. The
classification model was only used to assess the ability of
IgG N-glycans to be used as diagnostic biomarkers for
disease; therefore, in the classification model there was
no adjustment for the effect of age, sex, BMI, WHR, SBP,
DBP, FBG and RHR. A receiver operating characteristic
(ROC) curve was developed for the calculation of the
area under the cure (AUC) with a 95% CI.
Data analysis was performed using SPSS Statistics
version 21.0 for Windows (IBM Corp., Armonk, NY,
USA), SAS software version 9.2 (SAS Institute, Chicago, IL, USA) and R version 3.3.2 (R Core Team 2016).
All reported P values were two-sided, and P < 0.05
was considered statistically significant. Particularly,
P < 0.05/57 (0.0009) was considered to be statistically significant in the analysis of glycans to correct for multiple
comparisons.

Results
Description of clinical traits

Among the 913 recruited participants, 598 (64.50%) had
a complete dataset of blood measurements and glycan
traits and were included in the further analysis. In total,
8 clinical traits were described and compared between
the dyslipidaemia and control groups (Table 1). Most of
the traits (6 out of 8) were significantly different between
the two groups (P < 0.05). The number of males and the
values of age, BMI, WHR, FBG, and SBP in the dyslipidaemia group were significantly higher than those in the
control group.
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Table 1 Demographic and biochemical characteristics of the participants
Parameters

Total (n = 598)

Dyslipidaemia (n = 150)

Controls (n = 448)

P*

Number of male (%)

198 (33.11%)

76 (50.67%)

122 (27.23%)

< 0.001

Age (years)
BMI (kg/m2)
WHR
FBG (mmol/L)
SBP (mmHg)
DBP (mmHg)
RHR (beats/min)

47.35 ± 6.59

24.59 ± 3.23

0.82 ± 0.07

5.35 ± 0.83

48.89 ± 7.02

25.43 ± 3.65
0.85 ± 0.07

5.58 ± 0.99

46.84 ± 6.36

24.28 ± 3.04
0.81 ± 0.07

< 0.001

77.93 ± 10.20

< 0.001

119.50 ± 13.84

117.26 ± 15.06

76.09 ± 9.59

76.29 ± 8.91

76.13 ± 9.73

82.06 ± 10.87

< 0.001

5.29 ± 0.77

117.69 ± 14.05
78.78 ± 10.46

0.001
< 0.001

0.108
0.859

BMI body mass index, WHR waist–hip ratio, FBG fasting blood triglycerides, SBP systolic blood pressure, DBP diastolic blood pressure, RHR resting heart rate
* Statistically significant at significant level of 0.05

Principal component analysis (PCA)

As shown in Additional file 3: Figure S1, the significant
correlation coefficients in independent variables ranged
from 0.08 to 0.89. PCA was used to combine a few variables to several principal components in order to reduce
the multicollinearity of independent variables. The resulting Prin. 1 and Prin. 2 explained up to 54.78% of variance
in SBP, DBP, FBG, RHR, age, BMI and WHR (Prin.1 = 0.7
73 × SBP + 0.783 × DBP + 0.575 × FBG + 0.106 × RHR +
0.352 × Age + 0.688 × BMI + 0.733 × WHR, Prin.2 = 0.3
61 × SBP + 0.364 × DBP − 0.176 × FBG + 0.739 × RHR −
0.370 × Age − 0.246 × BMI − 0.329 × WHR). The resulting Prin. 3 and Prin. 4 explained up to 85.65% of variance
in TC, TG, HDL and LDL (Prin.3 = 0.985 × TC + 0.134
× TG + 0.444 × HDL + 0.923 × LDL, Prin.4 = 0.133 × TC
+ 0.889 × TG − 0.755 × HDL + 0.092 × LDL). Therefore,
in the analysis of the association between IgG N-glycans
and blood lipids, the principal components of blood
lipids (Prin. 3 and Prin. 4) were used as independent variables instead of blood lipids, and they were adjusted for
confounding factors (sex, Prin. 1 and Prin. 2).

initial traits and 7 derived traits in the IgG glycome were
significantly associated with blood lipids after adjusting
for the effects of sex, age, BMI, WHR, FBG, RHR, SBP
and DBP (P < 0.05). Detailed information is shown in the
supplemental content (Additional file 5: Table S4).
Multivariate analyses by canonical correlation analysis
(CCA)

The results of CCA showed that there are 4 pairs of
canonical variables, with canonical correlations of 0.390
(F = 2.44, P < 0.001), 0.324 (F = 1.88, P < 0.001), 0.240
(F = 1.39, P = 0.053) and 0.197 (F = 1.16, P = 0.282) for
each successive pair by the CCA. The first and the second canonical sets were statistically significant, indicating that N-glycan structures were significantly correlated
with the blood lipids. As shown in Fig. 1, 10 initial traits
(GP4, GP6, GP9-12, GP14, GP17-18 and GP23) tended to
be significantly associated with TC, TG and LDL levels in
the first canonical set. In addition, the level of GP11 was
strongly associated with canonical variables with a loading of 0.645, while the response variable with the highest
canonical loading was 0.781 (TC).

The association of IgG N‑glycans with blood lipids

Classification of dyslipidaemia using IgG N‑glycans

The results of the normal distribution tests of glycans are
shown in Additional file 4: Table S3. Of the 23 directly
measured glycans, 16 were not abnormally distributed
(P < 0.10). Therefore, a GLM was used to estimate the
effect of the principal components of blood lipids (Prin.
3 and Prin. 4) on glycosylation, adjusting for confounding factors (sex, Prin. 1 and Prin. 2). In total, 2 GPs in
the IgG N-glycans were significantly associated with
blood lipids after adjusting for the effects of sex, age,
BMI, WHR, FBG, RHR, SBP and DBP (P < 0.05/57). As
shown in Table 2, TC, TG and LDL were positively correlated with GP6, while they were negatively correlated
with GP18. In addition, HDL negatively correlated with
GP6 but positively correlated with GP18. Furthermore, 9

Among the 23 GPs, 9 GPs (GP1, GP4, GP5, GP6, GP11,
GP14, GP18, GP20 and GP21) were found to be significantly different in participants with dyslipidaemia than
in controls after adjusting for confounding factors (sex,
Prin. 1 and Prin. 2) (Fig. 2 and Additional file 6: Table S5).
As shown in Additional file 7: Figure S2, the significant
correlation coefficients in independent variables ranged
from 0.11 to 0.79. The LASSO method was used to select
IgG N-glycans in order to reduce the dimension of data.
The remaining glycans used by the LASSO method are
listed in Additional file 8: Table S6. The classification
model, incorporating significant IgG N-glycans, was able
to distinguish dyslipidaemia from controls, and the AUC
was 0.692 (95% CI 0.644–0.740) (Fig. 3).
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Table 2 Associations between IgG glycan and blood lipids
IgG glycans

Prin. 3
β (95% CI)a

Prin. 4
β (95% CI)b

P

P

Initial measurements
GP2

0.046 (0.006 to 0.087)

0.023*

GP4

0.035 (0.014 to 0.056)

0.001*

GP5

0.035 (0.014 to 0.055)

0.001*

GP6

0.036 (0.015 to 0.057)

< 0.001**

GP11

0.020 (0.004 to 0.036)

0.013*

GP14

− 0.022 (− 0.037 to 0.006)

GP18
GP20
GP21

− 0.012 (− 0.055 to 0.032)

− 0.015 (− 0.039 to 0.010)
0.019 (− 0.006 to 0.044)

− 0.010 (− 0.034 to 0.014)
0.017 (− 0.001 to 0.035)

0.596
0.237
0.130
0.395
0.066

0.006*

0.004 (− 0.014 to 0.022)

0.642

− 0.033 (− 0.051 to 0.015)

< 0.001**

0.006 (− 0.015 to 0.026)

0.604

0.014 (− 0.015 to 0.042)

0.336

0.051 (0.018 to 0.084)

0.003*

0.024 (0.004 to 0.045)

0.020*

0.025 (0.001 to 0.049)

0.041*

Sialylation
FGS/(FG + FGS)

FGS/(F + FG + FGS)

Bisecting GlcNAc

− 0.014 (− 0.025 to 0.003)

− 0.023 (− 0.037 to 0.008)

0.013*

0.001 (− 0.011 to 0.014)

0.840

0.003*

0.006 (− 0.012 to 0.023)

0.527

− 0.008 (− 0.030 to 0.014)

FBStotal/FStotal

0.021 (0.002 to 0.041)

0.032*

FBS2/FS2

0.020 (0.001 to 0.038)

0.039*

FBS2/(FS2 + FBS2)

0.011 (0.001 to 0.020)

G0n
G2n

0.498

0.005 (− 0.016 to 0.023)

0.660

0.034*

0.002 (− 0.009 to 0.013)

0.740

0.029 (0.012 to 0.046)

0.001*

–0.013 (− 0.033 to 0.007)

0.212

− 0.026 (− 0.043 to 0.009)

0.003*

0.008 (− 0.013 to 0.027)

0.476

Galactosylation

Prin.1 = 0.773 × SBP + 0.783 × DBP + 0.575 × FBG + 0.106 × RHR + 0.352 × Age + 0.688 × BMI + 0.733 × WHR
Prin.2 = 0.361 × SBP + 0.364 × DBP − 0.176 × FBG + 0.739 × RHR − 0.370 × Age − 0.246 × BMI − 0.329 × WHR
Prin.3 = 0.985 × TC + 0.134 × TG + 0.444 × HDL + 0.923 × LDL

Prin.4 = 0.133 × TC + 0.889 × TG-0.755 × HDL + 0.092 × LDL

BMI body mass index, WHR waist–hip ratio, FBG fasting blood glucose, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, TG total
triglycerides, HDL high-density lipoprotein, LDL low-density lipoprotein, RHR resting heart rate
a

Adjusted for the effects of sex, Prin.1, Prin.2 and Prin.4

b

Adjusted for the effects of sex, Prin.1, Prin.2 and Prin.3

* Statistically significant associations between two variables are shown, P < 0.05
** Statistically significant associations between two variables are shown, P < 0.05/57 = 0.0009

Discussion
Dyslipidaemia is one of the most important risk factors
for atherosclerosis, which triggers the development of
various cardiovascular and cerebrovascular diseases [13–
16]. The increased TC, TG and LDL and the decreased
HDL could be major public health problems; therefore,
the identification of biomarkers that might provide new
avenues for the prevention and treatment of dyslipidaemia is urgently needed. To our knowledge, this is the first
study to investigate the association of IgG N-glycans with
blood lipids and dyslipidaemia.
In the present study, the levels of TC, TG and LDL
were positively associated with the levels of GP4 and
GP6, while they were negatively correlated with the
level of GP18. Furthermore, the results were consistent
with those in CCA, in which N-glycan structures were
related with blood lipids. GP4 and GP6 are agalactosylated glycans and share the derived trait G0n, which

contains nearly the all glycans without galactose. In
parallel, GP18 contains 2 galactoses, which was negatively correlated with blood lipids. In addition, GP6 that
contains a bisecting GlcNAc was positively associated
with blood lipids, while a significant negative correlation existed between blood lipids and GP18, in which 1
sialic acid was found. This is consistent with the results
of the association between the derived traits in the IgG
glycome and blood lipids. Our findings indicated that
the associations between the blood lipids and IgG glycome were independently significant, with a negative
association with diagalactosylation and sialylation and
a positive association with bisecting agalactosylation
and N-acetylgucosylation. Furthermore, the loss of
galactose and sialic acid and the addition of a bisecting GlcNAc were consistently observed in patients with
dyslipidaemia. The changes of IgG N-glycosylation in
dyslipidaemia are consistent with the results of type 2
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Fig. 1 Canonical structures of the normalized IgG N-glycan and blood lipids in the first canonical set. The absolute value of canonical loadings
greater than 0.30 was significant loadings. All of the variables are sorted by the absolute value of their canonical loadings. The positive relationships
are represented in black boxes, while negative relationships are showed in red boxes. TC total cholesterol, TG total triglycerides, HDL high-density
lipoprotein, LDL low-density lipoprotein
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Fig. 2 Odds ratios (OR) and 95% confidence intervals (95% CI) for the associations of the normalized glycan variables in dyslipidaemia vs controls
(adjusted for sex, Prin.1 and Prin.2)

Fig. 3 Receiver operating characteristic (ROC) curve analysis in
regard to binary logistic regression in the prediction of dyslipidaemia.
AUC area under the cure; GP4, GP6, GP14, GP18, GP20 and GP21
included in the final model

diabetes, hypertension and ischemic stroke [26, 27, 29,
42].
N-Glycans that are attached to the Fc portion of IgG
are important modulators of IgG effector functions [5],
and even slight changes in IgG glycosylation can direct
pro- and anti-inflammatory actions of immunoglobulins [1, 4]. The decreased IgG galactosylation in rheumatoid arthritis was first reported nearly 32 years ago [43],
and recently, the same type of change in IgG glycosylation has been reported in a number of autoimmune and

inflammatory diseases [7, 9, 10, 12]. In addition, IgG glycosylation correlates with ageing, obesity, hypertension
and cancer [24, 25, 27, 31]. It can be speculated that the
loss of galactose is not disease specific but is a general
phenomenon that is associated with reducing the antiinflammatory function of circulating IgG. The addition
of sialic acid dramatically changes the physiological role
of IgGs, converting them from pro-inflammatory to antiinflammatory agents [6, 44]. In the interactions between
different functional elements of IgG glycosylation, it
has been shown that the presence of bisecting GlcNAcs
reduce galactosylated IgGs [6, 45, 46]. Accumulating evidence indicates that changes in IgG glycosylation mechanism could be part of the molecular mechanism leading
to the promotion of inflammation [6, 8, 44, 47]; therefore,
our results indicate inflammation as one of characteristics in dyslipidaemia that can increase the risk of developing other related disorders. This hypothesis is supported
by our findings that IgG N-glycosylation is significantly
associated with blood lipids and dyslipidaemia.
Previous studies have shown that the inflammatory role
of IgG N-glycosylation is associated with the risk factors
of dyslipidaemia [48] including aging and obesity [24,
25]. Inflammation, which is characteristic of aging and
obesity, is a process associated with different disorders,
such as dyslipidaemia [49]. Inflammatory disorders can
lead to the activation of several signalling transduction
pathways, inflammatory cytokine chemokine production and cell migration, all of which can influence lipid
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metabolism [49–52]. Interleukin 6 (IL-6) has been implicated in the pathogenesis of several immune-mediated
diseases, and monoclonal antibodies directed against
the IL-6 receptor have been developed to treat different
inflammatory diseases [53]. IL-6 and interleukin 6 signal
transducer (IL6ST) have been identified as dyslipidaemia
susceptibility loci [54, 55]. IL6ST has been identified to
have the capability to regulate galactosylation of IgG in
a genome-wide association study of IgG N-glycosylation
[12]. According to the law of Mendelian randomization
[56, 57], the genetic loci IL6ST is associated with IgG
N-glycosylation and has an effect on dyslipidaemia, indicating that the change of galactosylation and inflammation is the intermediate phenotype between IL6ST and
dyslipidaemia and is thus the causal factor of dyslipidaemia. However, this will need to be further explored and
validated.
The aberrant glycosylation which induces inflammation may provide exciting insights into the pathogenesis
of dyslipidaemia. However, causation is difficult to verify,
and the observed changes may be the consequence rather
than cause of the disease. Dyslipidaemia accompanied by
adipocytes that can produce and secrete cytokines and
adipokines [58] may thus affect the structural integrity
of IgG glycans, where IgG plays a crucial role in the activation of complement, interacts with Fc receptors and
affects antibody-dependent cell mediated cytotoxicity
(ADCC) [5]. Dyslipidaemia, as a basic metabolic disease,
may trigger changes in IgG glycosylation accompanied by
inflammation that can lead to related diseases. Therefore,
the casual effect between IgG glycosylation and dyslipidaemia remains unclear.
There are several potential limitations in this study that
should be recognized. First, the study was performed
with a relatively small sample population. Multiple correction was not used when we selected the initial glycans
as diagnostic biomarkers, which may have led to false
positive errors. However, to overcome this, the method
of reducing the dimensions of data, including PCA and
CCA, were applied to examine the association between
level of N-glycans and blood lipids. The merit of PCA is
that it explores all of the information from principal components, while the merit of CCA is to explore all of the
information from two sets of variables; therefore, PCA
and CCA help to solve the problem of multicollinearity
that is induced by the similarities of the variables. Second, our study is a cross-sectional study, bringing the
bias of diagnosis of dyslipidaemia cases. It lacks information regarding the time sequence of events; therefore, we
cannot conclude the causal relationship of IgG glycosylation and dyslipidaemia. In addition, the present study is
a pilot study to explore the association between N-glycans and blood lipids and dyslipidaemia. Further cohort
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studies or Mendelian randomization studies [57, 58] with
larger sample sizes are needed to provide a more definite
explanation about the relationships between N-glycan
structures and dyslipidaemia.

Conclusion
In conclusion, the present study showed a possible association between blood lipids and the observed loss of
galactose and sialic acid, as well as the addition of bisecting GlcNAcs which might be related to the chronic
inflammation accompanying the development of dyslipidaemia. Moreover, IgG N-glycosylation profiles may
serve as potential biomarkers for dyslipidaemia, contributing to a move towards personalized medicine. Future
studies focused on the mechanisms underlying the causal
association of IgG glycosylation and blood lipids or dyslipidaemia are needed.
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